• PharmAthene Inc., of Annapolis, Md., said the FDA lifted the clinical hold placed on a proposed Phase II study of SparVax, a next-generation recombinant anthrax vaccine. In a letter to the company, the FDA acknowledged that PharmAthene had satisfactorily addressed all of the agency's clinical hold issues and that the hold had been lifted, effective immediately.